Advertisement

International Journal of Colorectal Disease

, Volume 23, Issue 10, pp 985–992 | Cite as

Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases

  • A. Damms
  • S. C. Bischoff
Original Article

Abstract

Aims

Objective of this study was to compare the assay characteristics of a new fecal calprotectin rapid test with an enzyme-linked immunosorbent assay (ELISA). The second aim was to assess the potential of measuring fecal calprotectin as screening method for intestinal inflammation and colorectal malignancies.

Patients and methods

One hundred forty patients with lower gastrointestinal symptoms referred to colonoscopy provided fecal samples (56, control group; 18, diverticulosis; 29, colorectal adenoma; 8, colorectal carcinoma (CRC); 18, active inflammatory bowel disease (IBD); 11, intestinal infections). Feces were analyzed by two assay methods.

Results

Compared to the control group (median 25.8 µg/g), calprotectin levels were significantly increased in adenoma (66.3 µg/g), CRC (164 µg/g), intestinal infections (306 µg/g), and active IBD (797 µg/g). An adequate diagnostic accuracy could be found for active IBD with a sensitivity, specificity, and an area under the curve (AUC) of 100%, 79%, and 0.955 (ELISA) vs. 89%, 80%, and 0.896 (rapid test). Similar results were obtained for CRC (100%, 79%, 0.922 vs. 100%, 80%, 0.948) whereas in adenomas a low sensitivity, specificity, and AUC of 55%, 79%, and 0.686 vs. 52%, 80%, and 0.666 were found for fecal calprotectin.

Conclusions

Both fecal calprotectin assays are effective in identifying active IBD and CRC but lack analytical sensitivity in separating CRC from adenoma as well as adenoma from the control group. The new calprotectin rapid test is a convenient method for assessing the calprotectin level in an outpatient setting. Henceforth, it provides a precondition for the fecal calprotectin method to challenge fecal occult blood testing in further evaluations.

Keywords

Fecal calprotectin Inflammatory bowel disease Carcinoma Adenoma Diverticulosis 

Notes

Acknowledgements

The authors gratefully acknowledge the excellent assistance of Prof. W. Zoller, MD, A. Schreiber, MD, (Katharinenhospital), E. Fröhlich, MD, M. Schmidt, MD, (Karl-Olga-Hospital), Prof. E. Stange, MD, (Robert-Bosch-Hospital), H. Gölkel, MD, Th. Bühler MD, Prof. B. Klump, MD, K. Teubner, MD, D. Vogler, MD, A. Maier, MD, and A. Mühlhöfer, MD, in recruiting patients and kindly providing samples.

References

  1. 1.
    Gearry R, Barclay M, Florkowski C, George P, Walmsley T (2005) Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. NZMJ 118:1444–1451Google Scholar
  2. 2.
    Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F et al (2003) Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49:861–867PubMedCrossRefGoogle Scholar
  3. 3.
    Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54:364–368PubMedCrossRefGoogle Scholar
  4. 4.
    Gaya D, Mackenzie JFR (2002) Faecal calprotectin: a bright future for assessing disease activity in Crohn’s disease. Q J Med 95:557–558Google Scholar
  5. 5.
    Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ et al (2000) Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 95:2831–2837PubMedCrossRefGoogle Scholar
  6. 6.
    Poullis A, Foster R, Northfield TC, Mendall MA (2002) Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 16:675–681PubMedCrossRefGoogle Scholar
  7. 7.
    Røseth AG, Schmidt PN, Fagherol MK (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with Inflammatory bowel disease. Scand J Gastroenterol 34:50–54PubMedCrossRefGoogle Scholar
  8. 8.
    Røseth AG, Aadland E, Grzyb K (2004) Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39:1017–1020PubMedCrossRefGoogle Scholar
  9. 9.
    Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S et al (2000) A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47:506–513PubMedCrossRefGoogle Scholar
  10. 10.
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive in relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22PubMedCrossRefGoogle Scholar
  11. 11.
    Tibble JA, Bjarnason I (2001) Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 7:460–465PubMedGoogle Scholar
  12. 12.
    Vermeire S, Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic or unnecessary toys? Gut 55:426–431PubMedCrossRefGoogle Scholar
  13. 13.
    Johne B, Kronborg O, Tøn H, Kristinsson J, Fuglerud P (2001) A new faecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous methods. Scand J Gastroenterol 36:291–296PubMedCrossRefGoogle Scholar
  14. 14.
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (1998) Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321CrossRefGoogle Scholar
  15. 15.
    Kristinsson J, Armbruster CHR, Ugstad M, Kriwanek S, Nygaard K, Ton H et al (2001) Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 36:202–207PubMedGoogle Scholar
  16. 16.
    Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA (2003) Prospective evaluation of fecal calprotectin as screening biomarker for colorectal neoplasia. Am J Gastroenterol 98:2299–2305PubMedCrossRefGoogle Scholar
  17. 17.
    Poullis A, Foster R, Shetty A, Fagherol MK, Mendall MA (2004) Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomark Prev 13:279–284CrossRefGoogle Scholar
  18. 18.
    Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K et al (1993) Fecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 28:1073–1076PubMedCrossRefGoogle Scholar
  19. 19.
    Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagherol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408PubMedCrossRefGoogle Scholar
  20. 20.
    Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH et al (2000) Faecal calprotectin levels in a high risk population of colorectal neoplasia. Gut 46:795–800PubMedCrossRefGoogle Scholar
  21. 21.
    Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK (1990) Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336:763–765PubMedCrossRefGoogle Scholar
  22. 22.
    Yui S, Mikami M, Tsurumaki K, Yamazaki M (1997) Growth inhibitory and apoptosis inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 61:50–57PubMedGoogle Scholar
  23. 23.
    Fagherol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I (1990) Calprotectin (the L1 leucocyte protein). In: Smith VL, Dedman JR (eds) Stimulus response coupling: the role of intracellular calcium-binding proteins. CRC, Boca Raton, pp 187–210Google Scholar
  24. 24.
    Brun JG, Ulvestad E, Fagherol MK, Jonsson R (1994) Effects of human calprotectin (L1) on in vitro immunoglobulin syntheses. Scand J Immunol 40:675–680PubMedCrossRefGoogle Scholar
  25. 25.
    Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF et al (1997) Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol 50:113–123Google Scholar
  26. 26.
    Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14:841–845PubMedCrossRefGoogle Scholar
  27. 27.
    Røseth AG, Fagherol MK, Aadland E, Schjonsby H (1992) Assessment of the neutrophil dominating protein calprotectin in feces. Scand J Gastroenterol 27:793–798PubMedCrossRefGoogle Scholar
  28. 28.
    Tibble JA, Sigthorsson G, Foster R, Fagherol MK, Røseth A, Bjarnasson I (1999) High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 45:362–366PubMedCrossRefGoogle Scholar
  29. 29.
    Tibble JA, Sigthorsson G, Foster R et al (1998) NSAID enteropathy: a new simple diagnostic test. Gut 42:142Google Scholar
  30. 30.
    Fagherol MK (2000) Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 356:1783–1784CrossRefGoogle Scholar
  31. 31.
    Husebye E, Tøn H, Johne B (2001) Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 96(9):2683–2687PubMedGoogle Scholar
  32. 32.
    von Roon CA, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP et al (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102:1–11CrossRefGoogle Scholar
  33. 33.
    Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I (2002) Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 123:450–460PubMedCrossRefGoogle Scholar
  34. 34.
    D’Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG et al (2007) Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 22:429–437PubMedCrossRefGoogle Scholar
  35. 35.
    Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B et al (2001) Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 64:104–110PubMedCrossRefGoogle Scholar
  36. 36.
    Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH (2004) Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53:1329–1333PubMedCrossRefGoogle Scholar
  37. 37.
    Fagerberg UL, Lööf L, Myrdal U, Hansson L-O, Finkel Y (2005) Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. JPGN 40:450–455PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Nutritional Medicine (180)University of HohenheimStuttgartGermany

Personalised recommendations